{
    "clinical_study": {
        "@rank": "63721", 
        "arm_group": [
            {
                "arm_group_label": "Mg Oxide", 
                "description": "Mg Oxide (Mg\u00ae, 21st Century\u00ae) 250 mg orally for 4 weeks"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "placebo 1 tab TDS"
            }
        ], 
        "brief_summary": {
            "textblock": "Hyperphosphatemia is a common problem in hemodialysis (HD) patients. Different chelators for\n      control of Hyperphosphatemia are used.  The aim of this study was to assess the effect of\n      magnesium oxide (Mg Oxide) on the control of serum phosphorus (P) level and evaluation of\n      its side effects in hemodialysis patients."
        }, 
        "brief_title": "The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Hyperphosphatemia", 
        "condition_browse": {
            "mesh_term": "Hyperphosphatemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        hemodialysis with duration>3 months serum P level >5.5 mg/dl serum Ca>8 mg/dl.\n\n        Exclusion Criteria:\n\n        Mg level >3 mg/dl"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "hemodialysis patients"
            }
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01854437", 
            "org_study_id": "1391"
        }, 
        "intervention": {
            "arm_group_label": "Mg Oxide", 
            "description": "250 mg orally for 4 weeks", 
            "intervention_name": "Mg Oxide", 
            "intervention_type": "Drug", 
            "other_name": "(Mg\u00ae, 21st Century\u00ae)"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "mg oxide", 
            "hyperphosphatemia", 
            "plasma phosphor level"
        ], 
        "lastchanged_date": "May 12, 2013", 
        "link": {
            "description": "Related Info", 
            "url": "http://www.pubmed.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Shiraz", 
                    "country": "Iran, Islamic Republic of", 
                    "state": "Fars", 
                    "zip": "o98-711"
                }, 
                "name": "Shiraz University Hemodialysis Center"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_groups": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "plasma phosphate level", 
            "safety_issue": "Yes", 
            "time_frame": "4 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01854437"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shiraz University of Medical Sciences", 
            "investigator_full_name": "Maryam Pakfetrat", 
            "investigator_title": "associated professor of shiraz Shiraz University of Medical Sciences", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Shiraz University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shiraz University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "4 Months", 
        "verification_date": "May 2013"
    }
}